Statements (82)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:brand |
gptkb:Ingrezza
|
| gptkbp:category |
gptkb:unknown
gptkb:C |
| gptkbp:clinical_trial |
Phase 3
KINECT 3 KINECT 4 KINECT 1 KINECT 2 |
| gptkbp:clinical_use |
long-term management
neuroleptic-induced movement disorders |
| gptkbp:contraindication |
hypersensitivity to valbenazine
|
| gptkbp:dosage_form |
gptkb:capsule
80 mg once daily 40 mg once daily |
| gptkbp:drug_interactions |
MAO inhibitors
CYP2 D6 inhibitors CYP3 A4 inhibitors |
| gptkbp:effective_date |
gptkb:2017
|
| gptkbp:excretion |
urine
|
| gptkbp:formulation |
capsule formulation
capsule 40 mg capsule 80 mg |
| https://www.w3.org/2000/01/rdf-schema#label |
Ingrezza
|
| gptkbp:indication |
treatment of movement disorders
|
| gptkbp:ingredients |
gptkb:valbenazine
|
| gptkbp:interacts_with |
MAO inhibitors
dopamine receptor antagonists |
| gptkbp:invention |
patented
|
| gptkbp:is_monitored_by |
movement disorders
mental health status |
| gptkbp:lifespan |
approximately 15 hours
|
| gptkbp:manufacturer |
gptkb:Neurocrine_Biosciences
|
| gptkbp:marketed_as |
gptkb:2017
gptkb:Canada gptkb:European_Union gptkb:United_States |
| gptkbp:mechanism_of_action |
VMAT2 inhibitor
|
| gptkbp:patient_population |
adults
pediatric patients |
| gptkbp:pharmacokinetics |
metabolized by CYP2 D6
|
| gptkbp:previous_name |
gptkb:valbenazine
|
| gptkbp:related_products |
gptkb:deutetrabenazine
gptkb:tetrabenazine |
| gptkbp:requires |
available online
|
| gptkbp:research_focus |
neuropsychiatric disorders
|
| gptkbp:route_of_administration |
oral
|
| gptkbp:safety_measures |
not for use in pregnancy
risk of QT prolongation not for use in breastfeeding risk of sedation not approved for use in children under 18 |
| gptkbp:side_effect |
gptkb:depression
anxiety dizziness fatigue headache nausea abdominal pain dry eyes vomiting diarrhea restlessness insomnia constipation dry mouth weight gain blurred vision increased appetite nasopharyngitis somnolence orthostatic hypotension |
| gptkbp:storage |
room temperature
|
| gptkbp:structure |
C19 H26 N2 O
|
| gptkbp:support |
granted by FDA
granted by EMA |
| gptkbp:trade |
gptkb:Ingrezza
|
| gptkbp:type_of_care |
important for efficacy
|
| gptkbp:used_for |
treatment of tardive dyskinesia
|
| gptkbp:bfsParent |
gptkb:Neurocrine_Biosciences
|
| gptkbp:bfsLayer |
5
|